Kornimate/medical-research-clean huggingface dataset:
depressed aire gene expression causes immune cell dysfunction & autoimmunity in down syndrome

Conditions: Down Syndrome; Polyendocrinopathies, Autoimmune; Respiratory Tract Infections; Autoimmunity

Summary: this study plans to learn more about down syndrome. the investigators think there is a different level of the aire gene in individuals with down syndrome. the investigators think that the aire gene level can provide more insight about depressed immune cell function in individuals with down syndrome. patients are being asked to be in this research study because the investigators want to see if their blood contains more of less of the aire gene.

down syndrome (ds) is the most common chromosomal abnormality among live-born infants. through full or partial trisomy of chromosome 21, ds is associated with cognitive impairment, congenital malformations (particularly cardiovascular), and dysmorphic features. in addition, immunological abnormalities are much more prevalent in individuals with ds. for example, ds is associated with increased susceptibility to infection, as revealed in 2009 during the influenza pandemic where the likelihood of death was 300 times greater for ds patients than the general population. ds patients have increased frequencies of autoimmune disorders and leukemias, yet curiously, have a decreased risk for allergic diseases, particularly asthma. perhaps the most telling statistic for immunologic abnormality in ds patients is that respiratory tract infections are the most important cause of mortality in ds at all ages.our studies have identified aire as a master control gene that is aberrantly decreased in persons with ds, leading to autoimmunity and immunologic abnormalities. aire ("autoimmune regulator"), although encoded on chromosome 21, is also significantly reduced in expression in ds, where it may contribute to autoimmune and immune dysregulation. the investigators will test the hypothesis that immune dysfunction and autoimmune disease preferentially occur in ds as a consequence of deficient expression of aire in peripheral blood cells.

Eligibility criteria:
inclusion criteria: 1. age newborn up until the twenty-second birthday. 2. diagnosed with idiopathic or secondary pulmonary arterial hypertension as defined by a mean pulmonary artery pressure \> 25 mmhg at rest or \> 30 mmhg with exercise. 3. confirmed trisomy 21. 4. followed by the pulmonary hypertension program and sie center at the children's hospital. 5. the investigator or co-investigator must obtain written informed consent and assent where applicable before any study procedure is performed or data is collected. exclusion criteria: 1. any person older than 22 years of age 2. patients with sickle cell disease with pulmonary arterial hypertension (pah) as treatment is defined differently within this population. 3. in the opinion of the investigator, a patient who is unlikely to cooperate or complete the study for any reason.
electroacupuncture on modifying inflammatory levels of cytokines and metabolites in stroke patients.

Conditions: Ischemic Stroke; Acute

Summary: the study will make an association between the diagnosis of traditional chinese medicine that establishes that the syndrome of blood stagnation generates alteration in blood flow, vascular dysfunction, and damage to the endothelium. this process is like what occurs in a stroke. it will use electroacupuncture to change this chronic inflammatory process, and to know the effects and efficacy of this technique in the regulation and modulation of to treat extensive inflammatory diseases. however, this inflammatory response must be associated with serum cholesterol levels, since they are associated with a stroke between the ldl-c/hdl-c ratio and the prognosis after a stroke.

an adequate early standardized diagnosis of ischemic stroke uses different treatment protocols for these patients, depending on their complexity. therapeutic windows have been associated with better outcomes when reperfusion or recanalization occurs. someone has shown strongly related clinical outcome in ischemic stroke to the timely revascularization benefit of acupuncture in stroke patients; electroacupuncture intervention on metabolism is associated with effects on the anti-inflammatory mechanism and metabolic modulation, effects of electroacupuncture stimulation at different spinal segmental levels in a rat model of diabetes mellitus, and another vascular effect of electroacupuncture generate the modulation of the elasticity of the blood vessels. electroacupuncture (ea) stimulation is commonly applied in the treatment of ischemic stroke in the clinic. the efficacy of ea is associated with the acupuncture points, intensity, intervals, and duration of the intervention of the treatment for stroke. the inflammatory response might be associated with serum cholesterol levels since they are associated with a stroke between the ldl-c/hdl-c ratio and the prognosis after a stroke. this study evaluates the impact of electroacupuncture as a modifier of total cholesterol, hdl-c, and ldl-c blood levels and its anti-inflammatory effect in patients with cerebrovascular accidents. measurement of the post-electroacupuncture serum level (total cholesterol, hdl-c, ldl-c, and triglycerides) will provide adequate information on the influence that these risk factors have on blood vessels and vascular endothelium.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of patients with acute ischemic stroke 2. stroke diagnosed for the first time 3. must be able to respond to simple commands and tolerate the electroacupuncture exclusion criteria: 1. malignant cancer diagnosis 2. traumatic event 3. immunosuppressive patients 4. drug abuse 5. pregnant or lactating women 6. cardiac pacemaker patient

Keywords: stroke electroacupunture cholesterol
endoscopic submucosal dissection registry

Conditions: Neoplasm, Stomach; Neoplasm, Colorectal; Neoplasm, Esophagus; Neoplasm, Duodenal

Summary: this is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (esd) technique.

cases will be registered one by one in an electronic record, with the consent of the patient and respecting all legal requirements.

Eligibility criteria:
inclusion criteria: * epithelial pre-neoplastic (eg. adenoma, dysplasia) lesion on the esophageal, gastric, duodenal or colorectal mucosa * non-epithelial (eg. neuroendocrine tumor) lesion on the esophageal, gastric, duodenal or colorectal mucosa * age \> 18 years old * informed consent exclusion criteria: * age \< 18 years old * no informed consent
safety study of tetrathiomolybdate in patients with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this study will evaluate the safety of the administration of a copper chelating agent, tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous treatment. the primary endpoint for this study is safety with secondary endpoints including change in pulmonary function, exercise capacity, and quality of life.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pulmonary fibrosis * disease progression despite six months of treatment (steroids with/without azathioprine or cyclophosphamide) defined by at least one of the following: * increased symptoms * decline in forced vital capacity of at least 10% * decline in diffusion capacity for carbon monoxide of at least 20% * increased infiltrate on cxr or high resolution ct scan * taking \< 15 mg prednisone for at least 30 days prior to screening * age 35-80, inclusive * able to understand a written informed consent and comply with the study protocol exclusion criteria: * significant environmental exposure * diagnosis of collagen vascular disease * evidence of active infection * clinically significant cardiac disease: * myocardial infarction, coronary artery bypass or angioplasty within 6mo * unstable angina pectoris * congestive heart failure requiring hospitalization within 6 months * uncontrolled arrhythmia * poorly controlled or severe diabetes mellitus * pregnancy or lactation * women of childbearing potential not using a medically approved means of contraception (i.e. oral contraceptives, intrauterine devices, diaphragm, norplant) * current enrollment in another experimental protocol physiologic criteria: * fev1/fvc \< 0.60 laboratory criteria: * total bilirubin \> 1.5 x upper limit normal * ast or alt \> 3x upper limit normal * alkaline phosphatase \> 3x upper limit normal * white blood cell count \< 2,500/mm3 * hematocrit \< 30% * platelets \< 100,000/mm3 * prothrombin time inr \> 1.5
randomized multicenter phase ii/iii study with adjuvant gemcitabine versus neoadjuvant / adjuvant folfirinox for resectable pancreas carcinoma

Conditions: Resectable Prancreas Carcinoma

Summary: in this multicenter study, patients with resectable pancreatic carcinoma will be treated with (a) surgery followed by 6 cycles gemcitabine or (b) 4-6 cycles folfirinox followed by surgery followed by 4-6 cycles folfirinox. the overall survival between both therapies will be compared as well as other parameters.

this is a phase ii/iii randomized multicenter study. patients with resectable pancreatic carcinoma will be randomized in arm a (surgery plus adjuvant gemcitabine, 6 cycles) or arm b (4-6 cycles folfirinox neoadjuvant, 4-6 cycles folfirinox adjuvant). primary endpoint is the overall survival, secondary endpoints are progression-free survival, perioperative morbidity and mortality, rate of r0 resections, tolerability and feasibility of neoadjuvant folfirinox and others.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed adenocarcinoma of the pankreas. for histological confirmation, max. 3 tests are allowed. if no confirmation of carcinoma is possible, the patient can not be included into the study. 2. radiological confirmation of a locally limited curativ resectable (primarily resectale or borderline situation) pankreas carcinoma without distant metastases. 3. no prior pancreas resection 4. no prior cytostatic chemotherapy 5. female and male patients \> 18 and \<=75 years using contraception 6. ecog ≤ 1 7. medical resectability 8. granulocytes \> 1.500/µl 9. thrombocytes \> 100.000/µl 10. hemoglobin ≥ 8,0 g/dl 11. serumcreatinine ≤ 1.5x of normal value or creatinine-clearance \> 50 ml/min 12. written informed consent exclusion criteria: 1. endocrine pancreas carcinoma 2. locally advanced inoperable stages: non-resectable infiltration of v. porta or longway infiltration of a. mesenterica superior or infiltration of truncus coeliacus. 3. distant metastases 4. relapse 5. prior radiotherapy of measurable lesions 6. peritonealcarcinosis 7. malignant secondary disease, dated back \< 5 years (exeption: in-situ-carcinoma of the cervix, adequately treated skin basal cell carcinoma) 8. contraindication for operative resection 9. ecog ≥ 2 10. severe liver dysfunction (ast/alt\>3,5xuln, ap\>6xuln) 11. transhepatic drainage 12. active chd (symptoms present), cardiomyopathy or heart insufficiency stage iii-iv according to nyha and ef \< 45% 13. severe non-surgical accompanying diseases or acute infection 14. chronic diarrhea 15. chronic inflammable gastro-intestinal disease 16. peripheral polyneuropathy \> nci grade ii 17. pregnancy or lactation 18. hypersensibility or contraindication for gemcitabine, oxaliplatin, natriumfolinate, irinotecan or 5-fluorouracil 19. participation in another interventional trial

Keywords: pancreas cancer neoadjuvant chemotherapy folfirinox gemcitabine
prophylaxis of ventilator associated pneumonia by continuous lateral rotation therapy

Conditions: Pneumonia, Ventilator-Associated

Summary: hypothesis: ventilator associated pneumonia (vap) in critically ill patients may be prevented by continuous lateral rotation therapy (clrt) using specially designed, motor driven beds. patients are randomized to clrt or supine position if mechanically ventilated and not suffering from pneumonia or ards within 48 hours after intubation. prophylaxis of vap is standardized in both groups. primary endpoint is incidence of vap, secondary endpoints are length of ventilation, length of stay and mortality.


Eligibility criteria:
inclusion criteria: * mechanically ventilated * intubated not longer than 48 h * medical cause for icu admission * expected to be ventilated for \> 48 hours exclusion criteria: * pneumonia or ards present * postoperative patient

Keywords: prevention of ventilator associated pneumonia
auditory training and hearing aid satisfaction

Conditions: Hearing Impairment, Sensorineural

Summary: although hearing aids are the most common treatment for hearing loss, and have the potential to help seniors stay active and productive, almost 50% of them who receive hearing aids rarely if ever use them, a state of affairs sometimes referred to as "the hearing aid in the drawer" syndrome. clear's customized auditory brain training has been shown to be effective in improving adults' abilities to recognize speech, in reducing their perceptual effort associated with listening with a hearing loss, and in increasing their confidence to engage in everyday conversations. in the proposed research, we will determine whether older adults who receive hearing aids for the first time report higher satisfaction with their new hearing aids and have longer daily use time as a result of having completed clear's auditory brain training program for new hearing aid users.

auditory training as the potential to dramatically affect older persons' adjustment to a new hearing aid and to maximize the benefits they receive from wearing one. in turn, by wearing hearing aids, they experience easier and more successful communication patterns. they enhance their ability to engage in everyday conversations and will be able to become more socially involved with their family and friends. in this study we will try to determine the extent to which web-based clear auditory brain training, with concomitant support from a clear in-house audiologist, affects satisfaction with new hearing aids and increases daily use time. the study will include thirty adults over the age of 60 years who have received hearing aids for the first time. after an adjustment period, half will complete clear's auditory brain training program right away and the other half will complete it after a delay period, and both will complete a control condition. to establish the level of feasibility and clinical utility. we will measure hearing aid satisfaction, benefit ratings, and hearing aid use time.

Eligibility criteria:
inclusion criteria: * must be a native english speaker * must have a mild to severe bilateral sensorineural hearing loss * must be a candidate for new hearing aid(s) (have never used hearing aids) exclusion criteria: * cognitive impairment or any factors that would prohibit a participant from completing questionnaires * cognitive or speech production factors that would prohibit a participant from repeating words during a speech perception test.

Keywords: auditory training
testing of mobile monitoring system

Conditions: Orthopedic Disorder

Summary: we will complete a prospective, observational study comparing the accuracy of the mobile monitoring tool on identifying ssi compared to manual review.


Eligibility criteria:
inclusion criteria: * orthopaedic surgery patient at hospital 175 exclusion criteria: * no access to mobile phone
68ga-nota-exendin-4 pet/ct for the localization of insulinoma and diagnosis of nesidioblastosis

Conditions: Insulinoma; Nesidioblastosis

Summary: this is an open-label positron emission tomography/computed tomography (pet/ct) study to investigate the diagnostic performance and evaluation efficacy of 68ga-nota-exendin-4 in insulinoma and nesidioblastosis patients. a single dose of 55.5-111 mega-becquerel (mbq) 68ga-nota-exendin-4 will be injected intravenously. visual and semiquantitative method will be used to assess the pet/ct images.

68ga-nota-exendin-4 is an optimal probe targeting glp-1r. the investigators will determine the use of 68ga-nota-exendin-4 pet/ct in the detection of insulinomas, and to compare its diagnostic value with conventional imaging. glp-1r imaging, specifically expressed on pancreatic beta cell surface, might help with diagnosis of different types of nesidioblastosis (ie. focal or diffuse type), and may improve the treatment strategy of nesidioblastosis. the investigator will determine the use of 68ga-nota-exendin-4 pet/ct in differentiating nesidioblastosis.

Eligibility criteria:
inclusion criteria: * patients with hypoglycaemia in the presence of neuroglycopenic symptoms and documented whipple's triad. * biochemically proven endogenous hyperinsulinemic hypoglycaemia (plasma glucose concentration \ 3 µu/ml, and c-peptide \>0.6 ng/ml). * conventional imaging within 1 month * signed written consent * age above 6 years (congenital hyperinsulinemic with the symptoms onset in school age is also the subject of this study) exclusion criteria: * pregnancy * breastfeeding * renal function: serum creatinine \> 3.0 mg/dl * known allergy against exendin-4 * any medical condition that, in the opinion of the investigator, may significantly interfere with study compliance.

Keywords: pet/ct glucagon-like peptide-1 receptor (glp-1r) imaging
hd-tdcs: effects on the somatosensory system

Conditions: Acute Pain; Neuroplasticity; Brain Modulation; Somatosensory Function

Summary: the purpose of this study is to investigate the efficacy of high definition tdcs on different cortical targets in modulating the nociceptive system in the healthy subjects.

the investigators aim to investigate the efficacy of different hd-tdcs electrode configurations on modulating the somatosensory/nociceptive system. this is done to investigate the hypothesis, that different stimulation protocols can be used to modulate the somatosensory and nociceptive system, as shown in the previous studies, but that it is necessary to uncover the most efficient way to do so. the study uses a double-blinded, sham-controlled, longitudinal design, where quantitative sensory testing will be used to assess the somatosensory function of the participants before and after a receiving a specific configuration of hd-tdcs on three consecutive days.

Eligibility criteria:
inclusion criteria: * healthy men and women. * able to speak, read and understand english or danish. exclusion criteria: * pregnancy * drug addiction defined as the use of cannabis, opioids or other drugs * current use of opioids, antipsychotics, benzodiazepines * previous or current neurological, musculoskeletal, rheumatic, malignant, inflammatory or mental illnesses * current or prior chronic pain conditions * lack of ability to cooperate

Keywords: tdcs hd-tdcs somatosensory function qst quantitative sensory testing non-invasive brain stimulation nibs transcranial direct current stimulation
anlotinib in the treatment of advanced hepatocellular carcinoma (hcc)

Conditions: Cancer of Liver

Summary: this is a prospective, one-arm, exploratory clinical study to observe and evaluate the efficacy and safety of anlotinib hydrochloride capsules in patients with advanced liver cancer.


Eligibility criteria:
inclusion criteria: * age: 18 to 75 years old. * at least one measurable lesion (the length of spiral ct scan (\> 10mm) meets the requirements of rescist 1.1) is found in patients with hcc confirmed by histopathology or cytology or who meet the clinical diagnostic criteria. * inability or unwillingness to undergo surgery and transcatheter hepatic artery interventional therapy; if interventional therapy, radiotherapy or surgery has been accepted, it must be more than 4 weeks, and adverse reactions or wounds have fully recovered. * no treatment with sorafenib or other systemic treatment was received. patients who have used interventional chemotherapeutic drugs during interventional therapy may be enrolled in the group. * child-pugh liver function rating: grade a or b; bclc stage b or c. * ecog ps：0-2. * the life expectancy is more than 12 weeks. * the main organs are functioning normally, which meets the following criteria: (1) blood routine examination: a. hb \> 90 g/l; (no blood transfusion within 14 days) b. anc is more than 1.5 x /l; c. plt is more than 50 x /l; (2) biochemical examination: a. alt and ast \< 5_uln; b. tbil \< 1.5_uln; c. plasma cr \< 1.5_uln. * subjects volunteered to join the study, signed informed consent, good compliance, with follow-up. exclusion criteria: * hepatobiliary and mixed cell carcinomas and fiberboard cell carcinomas are known; other malignant tumors (except cured cutaneous basal cell carcinomas and cervical carcinoma in situ) have been reported in the past or at the same time. * pregnant or lactating women . * patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure \> 150 mmhg, diastolic blood pressure \> 100 mmhg), patients with myocardial ischemia or myocardial infarction above grade ii, arrhythmias with poor control (including qtc interval \> 450 ms) and cardiac insufficiency of grade iii-iv according to nyha standard. * inability to swallow, chronic diarrhea and intestinal obstruction significantly affect drug use and absorption. * there are clear concerns about gastrointestinal bleeding (such as local active ulcer lesions, fecal occult blood +) or more), and there is a history of gastrointestinal bleeding within 6 months. * central nervous system metastasis has occurred. * coagulation dysfunction (pt \> 16 s, aptt \> 43 s, tt \> 21 s, fbg \< 2 g/l), with bleeding tendency or undergoing thrombolysis or anticoagulation therapy. * have a history of mental illness or psychotropic drug abuse. * peritoneal effusion with clinical symptoms requires therapeutic abdominal puncture or drainage, or child-pugh score (\> 2).
the impact of diet liberalization on bowel preparation for colonoscopy

Conditions: Colonic Diseases

Summary: this study will evaluate the expansion of dietary options from clear liquids the entire day to a low reside breakfast and lunch for patients prior to undergoing bowel preparation with moviprep® and its effect on preparation quality for colonoscopy.

this study will evaluate the expansion of dietary options from clear liquids the entire day to a low reside breakfast and lunch for patients prior to undergoing bowel preparation with moviprep® and its effect on preparation quality for colonoscopy. moviprep® is a commercially available 2 liter bowel purgative for use before colonoscopy in adults 18 years of age or older that is comprised of polyethylene glycol-electrolyte solution (peg-els) plus sodium sulfate, sodium ascorbate, and ascorbic acid.

Eligibility criteria:
inclusion criteria: * elective outpatients \> 18 yrs undergoing colonoscopy exclusion criteria: * unable or unwilling to give informed consent * age \< 18 years * pregnant * breast feeding * gastroparesis - established or suspected * pseudo-obstruction - established or suspected * severe constipation (\< 1 bm a week) * bowel obstruction * colon resection * chronic nausea or vomiting * known glucose-6-phosphate dehydrogenase (g6pd) deficiency * peg allergy * significant psychiatric illness

Keywords: colonoscopy
helicobacter pylori screening at sohag university

Conditions: In Early Pregnancy

Summary: screen of helicobacter pylori in hyperemesis gravidarum in early pregnancy to detect the impact of the severity of the disease on pregnant women


Eligibility criteria:
inclusion criteria: * pregnant woman \<16wk exclusion criteria: * pregnant woman \>16wks